TY - JOUR AU - Rocke, Merle AU - Knochenhauer, Elena AU - Thams, Friederike AU - Antonenko, Daria AU - Fromm, Anna Elisabeth AU - Jansen, Nora AU - Aziziaram, Samaneh AU - Grittner, Ulrike AU - Schmidt, Sein AU - Vogelgesang, Antje AU - Brakemeier, Eva-Lotta AU - Flöel, Agnes TI - Neuromodulation through brain stimulation-assisted cognitive training in patients with post-chemotherapy subjective cognitive impairment (Neuromod-PCSCI) after breast cancer: study protocol for a double-blinded randomised controlled trial. JO - BMJ open VL - 15 IS - 5 SN - 2044-6055 CY - London PB - BMJ Publishing Group M1 - DZNE-2025-00632 SP - e096162 PY - 2025 AB - Breast cancer is the most common form of cancer in women. A considerable number of women with breast cancer who have been treated with chemotherapy subsequently develop neurological symptoms such as concentration and memory difficulties (also known as 'chemobrain'). Currently, there are no validated therapeutic approaches available to treat these symptoms. Cognitive training holds the potential to counteract cognitive impairment. Combining cognitive training with concurrent transcranial direct current stimulation (tDCS) could enhance and maintain the effects of this training, potentially providing a new approach to treat post-chemotherapy subjective cognitive impairment (PCSCI). With this study, we aim to investigate the effects of multi-session tDCS over the left dorsolateral prefrontal cortex in combination with cognitive training on cognition and quality of life in women with PCSCI.The Neuromod-PCSCI trial is a monocentric, randomised, double-blind, placebo-controlled study. Fifty-two women with PCSCI after breast cancer therapy will receive a 3-week tDCS-assisted cognitive training with anodal tDCS over the left dorsolateral prefrontal cortex (target intervention), compared with cognitive training plus sham tDCS (control intervention). Cognitive training will consist of a letter updating task. Primary outcome will be the performance in an untrained task (n-back task) after training. In addition, feasibility, safety and tolerability, as well as quality of life and performance in additional untrained tasks will be investigated. A follow-up visit will be performed 1 month after intervention to assess possible long-term effects. In an exploratory approach, structural and functional MRI will be acquired before the intervention and at post-intervention to identify possible neural predictors for successful intervention.Ethical approval was granted by the ethics committee of the University Medicine Greifswald (BB236/20). Results will be available through publications in peer-reviewed journals and presentations at national and international conferences.ClinicalTrials.gov; NCT04817566, registered on 26 March 2021. KW - Humans KW - Breast Neoplasms: drug therapy KW - Female KW - Transcranial Direct Current Stimulation: methods KW - Double-Blind Method KW - Quality of Life KW - Randomized Controlled Trials as Topic KW - Cognitive Behavioral Therapy: methods KW - Chemotherapy-Related Cognitive Impairment: therapy KW - Chemotherapy-Related Cognitive Impairment: etiology KW - Cognitive Dysfunction: therapy KW - Cognitive Dysfunction: chemically induced KW - Middle Aged KW - Adult KW - Dorsolateral Prefrontal Cortex KW - Prefrontal Cortex KW - Cognition KW - Antineoplastic Agents: adverse effects KW - Cognitive Training KW - CHEMOTHERAPY (Other) KW - Cognition (Other) KW - Quality of Life (Other) KW - Antineoplastic Agents (NLM Chemicals) LB - PUB:(DE-HGF)16 C6 - pmid:40398955 DO - DOI:10.1136/bmjopen-2024-096162 UR - https://pub.dzne.de/record/278796 ER -